ARTICLES BY LOUIS

• “Organizational Outsourcing” At Astex Pharmaceuticals

  10/30/2023

  After decades working at CDMOs, Matthew Johnson decided to give it a go directly pushing along NCEs at a biopharma. The company he selected for this new endeavor has an interesting organizational matrix – components of an international, external-internal supply chain.

• Oh, Oligonucleotides! Everybody Wants In

  10/23/2023

  “We’re working on oligonucleotides,” says the bubbling biotech. “We can do oligos!” cries the eager CDMO. So it’s a deal? Hang on, says Tony Sampognaro, Director, CMC Project Management, at oligo-focused Stoke Therapeutics.

• Outsourcing Needs More MBAs (Yes, You Read That Correctly)

  10/16/2023

  Tony Sampognaro of Stoke Therapeutics recently received his MBA. He thinks many others in our industry should do so as well. He believes its what we need to outsource more efficiently, and work better with CDMOs.

• Bristol Myers Squibb Buys Mirati: Signal Or Symptom?

  10/10/2023

  This discussion goes well beyond the recent Bristol Myers Squibb deal for Mirati Therapeutics, to thoughts on how we limit patent durations to provide for a robust generics market. Do we actually lower drug prices? 

• More Gene Therapy Outsourcing – Can It Be Quantified?

  10/9/2023

  According to ISR Reports inaugural Gene Therapy CDMO Benchmarking survey, well over half the respondents confirmed a complete manufacturing reliance on external partners. Outsourcing has sure come a long way ... more details within.

• CM² + AI = Better Manufacturing At Your CDMOs

  10/3/2023

  This is the final in our series pursuing the practical use of artificial intelligence (AI) in the biopharma supply chain, guided by Professor Tinglong Dai of Johns Hopkins. A look at continuous processing and monitoring, and AI.

• Big Pharma Advises Biotech On Outsourcing

  9/25/2023

  They say biotech taught pharma how to outsource. So what’s someone who has spent 31 years working in Big Pharma know about outsourcing from the vantage point of smaller organizations? A lot, it turns out.

• AI Beats Back Bad Batches

  9/21/2023

  “I look from a supply-chain perspective,” says AI / supply-chain expert Tingling Dai, “discovery, development, manufacture ... until we put them into clinical use.” And that involves, he says, “keeping track of multiple stakeholders.”

• AI, The Ghost In The Outsourcing Machine

  9/18/2023

  It’s time to get real about artificial intelligence applied specifically to drug development and manufacturing outsourcing; practical supply-chain enhancements to implement right now. Thoughts from an AI supply-chain expert. Part 1.

• In Year 20, “Biopharmaceutical” Remains The Same

  9/15/2023

  Each year, I present some takeaways to Outsourced Pharma readers from BioPlan's important annual survey on bioprocessing. This year, I notice our noisy nomenclature, and present a chart that indicates CDMOs will keep on keeping on.